Harm’s Way Polyglutamine Repeats and the Activation of an Apoptotic Pathway by Green, Douglas R.
Neuron
416
indirectly to some of these death receptors and recruitsHarm's Way: Polyglutamine Repeats
caspase-8, leading to its activation (see figure, panel A).and the Activation The second type of adaptor molecule is Apaf-1, which
of an Apoptotic Pathway aggregates upon binding to cytochrome c released from
mitochondria during apoptosis (Zhou et al., 1999). The
aggregated Apaf-1 recruits procaspase-9, leading to its
transcleavage and activation (see figure, panel B). TheseThe process of apoptosis, in which cells undergo a
two types of adaptor molecules help to define two typestightly controlled and coordinated death, proceeds via
of death pathway, one involving death receptors and onethe activation of caspase proteases that cleave key sub-
involving the mitochondria (and cytochrome c release).strates. The activation or inactivation of these substrates
Now there may be another. Sanchez et al. (1999) ex-is responsible for the ªpackagingº of the dying cell for
amined the ability of polyglutamine repeats of 50 orclearance by phagocytes and is probably responsible
more units to trigger caspase activation and apoptosisfor actually killing the cell in many cases. How the prote-
in cells transfected with the expression constructs. Theyases become activated, then, is of central importance
found that the cell death was blocked by a dominantto our understanding of cell life and death in a variety
negative FADD (containing only the bit that normallyof physiological and pathological situations. In the paper
binds to Fas) and by a dominant negative caspase-8.by Yuan and colleagues in this issue of Neuron (Sanchez
Both of these proteins effectively localized to the largeet al., 1999), the authors propose a novel pathway for
polyglutamine aggregates in the cells, suggesting thatthe activation of caspases by proteins with extended
procaspase-8 is similarly recruited. They showed thatpolyglutamine repeats of the sort associated with sev-
expression of a polyglutamine repeat led to endogenouseral neurodegenerative diseases, including Hunting-
caspase-8 appearing in an insoluble fraction in the cell,ton's disease, spinocerebellar ataxias, dentatorubral±
presumably with the insoluble polyglutamine aggre-pallidolyusian atrophy, and others (Perutz, 1999). They
gates. Thus, recruitment of procaspase-8 to the poly-suggest that polyglutamine repeat proteins assemble
into insoluble aggregates containing one of the cas- glutamine aggregates may play a role in polyglutamine-
pases, which becomes activated, leading to apoptosis. induced apoptosis. In support of this, they found that a
Although it is difficult to relate the in vitro studies to cell line lacking caspase-8 was resistant to polygluta-
in vivo disease, they show that this caspase, which is mine-induced apoptosis.
normally soluble, partitions with an insoluble fraction in The model in panel C of the figure is consistent with
extracts from the brains of several patients with Hunting- their observations. Polyglutamine repeats form aggre-
ton's disease. This raises the intriguing possibility that gates that bind to adaptor proteins such as FADD, which
cytosolic aggregation of polyglutamine repeat proteins has itself been shown to form filamentous structures
contributes to neurodegenerative disease via the re- in cells upon overexpression (Perez and White, 1998).
cruitment, binding, and activation of caspases. FADD (and perhaps other adaptor molecules) recruits
There are currently about a dozen human caspases procaspase-8, which transactivates. The ability of FADD
identified, and only a subset of these are known to be DN to block binding and activation of procaspase-8
involved in apoptosis. All caspases are expressed as suggests that the binding of this adaptor (and any other
single chain proenzymes with low proteolytic activity; relevant adaptor) is to a limited number of sites on the
upon cleavage, these autoassemble into tetramers and polyglutamine filament. A procaspase-8 with a mutated
increase their enzymatic activity about 100-fold (Ash- active site blocks caspase activation and apoptosis,
kenazi and Dixit, 1998) (see figure). This cleavage can presumably because it complexes with endogenous
occur in two ways. The first is via the action of another procaspase-8 but cannot participate in the transactiva-
protease. Active caspases can cleave procaspases to tion event. Whether other procaspases are present in
yield the active subunits, and this forms the basis for
the complex is not known, but procaspase-8, at least,
caspase cascades that amplify the effects of an active
appears to be required for caspase activation and sub-
caspase (see figure, panel D).
sequent death, at least in the cell lines examined.The second way in which procaspases are cleaved
Recent studies have shown that the formation of largeand activated is by bringing together two or more pro-
insoluble aggregates is not a requirement for apoptosiscaspase molecules such that the low proteolytic activity
induced by polyglutamine repeat proteins (e.g., Saudouof each proform can act on its neighbor to cleave and
et al., 1998). This does not rule out, however, the possi-activate it. This depends on the binding of adaptor mole-
bility that smaller polyglutamine polymers, perhapscules to protein interaction regions located within the
more closely resembling the ªdeath filamentsº formedprodomains of some of the procaspases (see figure)
by FADD and mentioned above, trigger apoptosis via(Green, 1998). The oligomerization of the adaptor mole-
recruitment of adaptor proteins and procaspases as de-cules therefore controls the activation of the caspase,
scribed here. Further, another recent study has shownwhich in turn can act on other caspases to activate
that while polyglutamine repeats can induce caspasethem.
activation, they also induce a caspase-independent cellSo far, only two types of functional adaptor molecules
death (Moulder et al., 1999). Interestingly, FADD hasare known. The first type forms complexes with the
also recently been found to be capable of inducing aintracellular domains of so-called ªdeath receptors,º
caspase-independent cell death (Kawahara et al., 1998).apoptosis-inducing members of the tumor necrosis fac-
It will be interesting to determine whether these phe-tor receptor family (Ashkenazi and Dixit, 1998). One of
these adaptors is FADD/MORT1, which binds directly or nomena are related.
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Pathways to Caspase Activation and Apo-
ptosis
(A) Transactivation of procaspase-8 by asso-
ciation with adaptors such as FADD and li-
gated death receptors. Binding of ligand to a
death receptor causes trimerization and as-
sembly of an intracellular complex that in-
cludes adaptor proteins (e.g., FADD) and pro-
caspases (e.g., procaspase-8). Bringing the
procaspase-8 molecules into close proximity
leads to their transactivation and processing
into mature caspase-8, which can then act on
other procaspases to activate them (arrows).
(B) Transactivation of procaspase-9 by asso-
ciation with aggregated Apaf-1, induced by
cytochrome c. Cytochrome c released from
mitochondria following a proapoptotic induc-
tion binds to Apaf-1, which causes it to
change conformation, aggregate, and bind
procaspase-9. Bringing the procaspase-9
molecules into close proximity leads to their
transactivation and processing into mature
caspase-9.
(C) Suggested aggregation and transactivation of procaspase-8 by association with polymerized polyglutamine repeat proteins. Polymerized
polyglutamine repeat proteins bind adaptor molecules such as FADD, which in turn bind procaspase-8. Procaspase-8 then transactivates as
in (A), leading to the generation of mature caspase-8.
(D) Active caspases produced by the processes in (A) through (C) cleave and activate other caspases, which in turn cleave key substrates to
orchestrate the apoptotic phenotype and death of the cell.
The extended polyglutamine repeats associated with Douglas R. Green
La Jolla Institute for Allergy and Immunologyseveral neurodegenerative diseases can aggregate in-
dependently of other influences in vitro, but in vivo this 10355 Science Drive Center
San Diego, California 92121may be facilitated through the action of ªtissueº transglu-
taminase, an enzyme that links glutamine to the e-amino
Selected Readinggroups of lysines on other proteins. In recent studies,
the polyglutamine repeat protein huntingtin was shown
Ashkenazi, A., and Dixit, V.M. (1998). Science 281, 1305±1308.to be an effective substrate for transglutaminase, and
Green, D.R. (1998). Cell 94, 695±698.the rate constant of the reaction increased with the
Igarashi, S., Koide, R., Shimohata, T., Yamada, M., Hayashi, Y.,length of the polyglutamine repeat (Kahlem et al., 1998).
Takano, H., Date, H., Oyake, M., Sato, T., Sato, A., et al. (1998). Nat.
Further, transglutaminase inhibitors blocked the forma- Genet. 18, 111±117.
tion of huntingtin polymers (Kahlem et al., 1998) and
Kahlem, P., Green, H., and Djian, P. (1998). Mol. Cell 1, 595±601.
the formation of filamentous aggregates and apoptosis
Kawahara, A., Ohsawa, Y., Matsumura, H., Uchiyama, Y., and Na-
induced by expression of the dentatorubral±pallidoly- gata, S. (1998). J. Cell Biol. 143, 1353±1360.
usian atrophy protein (Igarashi et al., 1998). Melino, G., Annicchiarico-Petruzzelli, M., Piredda, L., Candi, E., Gen-
But the possible role of transglutaminase in apoptosis tile, V., Davies, P.J., and Piacentini, M. (1994). Mol. Cell Biol. 14,
may be more general. For example, ectopic expression 6584±6596.
of the tissue transglutaminase gene can trigger apopto- Moulder, K.L., Onodera, O., Burke, J.R., Strittmatter, W.J., and John-
son, E.M., Jr. (1999). J. Neurosci. 19, 705±715.sis in cells from normal individuals (i.e., without polyglu-
tamine repeat disease), and expression of an antisense Perez, D., and White, E. (1998). J. Cell Biol. 141, 1255±1266.
construct for this gene was observed to block spontane- Perutz, M.F. (1999). Trends Biol. Sci. 24, 58±63.
ous and retinoic acid±induced apoptosis in a neuro- Sanchez, I., Xu, C.J., Juo, P., Kakizaka, A., Blenis, J., and Yuan, J.
(1999). Neuron 22, this issue, 623±633.blastoma cell line (Melino et al., 1994). One could envi-
sion that even in the absence of pathogenic proteins Saudou, F., Finkbeiner, S., Devys, D., and Greenberg, M.E. (1998).
Cell 95, 55±66.with extensive polyglutamine repeats, the action of
Zhou, H., Li, Y., Liu, X., and Wang, X. (1999). J. Biol. Chem., in press.transglutaminase in some circumstances can create
similar filamentous structures capable of recruiting
adaptor proteins and procaspases (such as FADD and
procaspase-8), leading to caspase activation and apo-
ptosis. Therefore, there may be various ways to trigger
the generation of ªdeath filamentsº that recruit procas-
pases and lead to apoptosis. If so, the studies of Yuan
and colleagues (Sanchez et al., 1999) may have done
more than suggest a mechanism for cell death in a
pathologic setting, they may have identified a new physi-
ological death pathway.
